- Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association
-
Cho Y, Choi JW, Kwon H, Kim KY, Lee BC, Chu HH, Lee DH, Lee HA, Kim GM, Oh JS, Hyun D, Lee IJ, Rhim H, Research Committee of the Korean Liver Cancer Association
- KMID: 2543980
- Clin Mol Hepatol.
- 2023 Jul;29(3):521-541.
- doi: 10.3350/cmh.2023.0202
Transarterial chemoembolization (TACE) was introduced in 1977 with the administration of chemotherapeutic agent to gelatin sponge particles through the hepatic artery in patients with hepatocellular carcinoma (HCC) and was established... -
- CITED
-
- Close
- SHARE
-
- Close
- HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?
-
Lee SK, Kwon JH
- KMID: 2544004
- Clin Mol Hepatol.
- 2023 Jul;29(3):825-827.
- doi: 10.3350/cmh.2023.0185
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence on Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”
-
Yeo YH, Samaan JS, Ng WH
- KMID: 2544003
- Clin Mol Hepatol.
- 2023 Jul;29(3):823-824.
- doi: 10.3350/cmh.2023.0182
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence on Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”
-
Yeo YH, Samaan JS, Ng WH
- KMID: 2544002
- Clin Mol Hepatol.
- 2023 Jul;29(3):821-822.
- doi: 10.3350/cmh.2023.0183
-
- CITED
-
- Close
- SHARE
-
- Close
- Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis
-
Hur MH, Cho Y, Kim DY, Lee JS, Kim GM, Kim HC, Sinn DH, Hyun D, Lee HA, Seo YS, Lee IJ, Park JW, Kim YJ
- KMID: 2543993
- Clin Mol Hepatol.
- 2023 Jul;29(3):763-778.
- doi: 10.3350/cmh.2023.0076
Background/Aims: Transarterial radioembolization (TARE) has shown promising results in treating advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). However, whether TARE can provide superior or comparable outcomes to... -
- CITED
-
- Close
- SHARE
-
- Close
- The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B
-
Mao X, Mak LY, Seto WK
- KMID: 2543987
- Clin Mol Hepatol.
- 2023 Jul;29(3):690-692.
- doi: 10.3350/cmh.2023.0173
-
- CITED
-
- Close
- SHARE
-
- Close
- Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”
-
Kleebayoon A, Wiwanitkit V
- KMID: 2543999
- Clin Mol Hepatol.
- 2023 Jul;29(3):815-816.
- doi: 10.3350/cmh.2023.0170
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence on Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”
-
Oh JH, Sinn DH
- KMID: 2544001
- Clin Mol Hepatol.
- 2023 Jul;29(3):820-820.
- doi: 10.3350/cmh.2023.0135
-
- CITED
-
- Close
- SHARE
-
- Close
- Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”
-
Ali H
- KMID: 2543998
- Clin Mol Hepatol.
- 2023 Jul;29(3):813-814.
- doi: 10.3350/cmh.2023.0120
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence on Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”
-
Han SK, Baik SK, Kim MY
- KMID: 2544000
- Clin Mol Hepatol.
- 2023 Jul;29(3):817-819.
- doi: 10.3350/cmh.2023.0155
-
- CITED
-
- Close
- SHARE
-
- Close
- Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma
-
Park J, Chung SW, Lee YB, Shin H, Hur MH, Cho H, Park MK, Youk J, Lee JY, Lee JO, Yu SJ, Kim YJ, Yoon JH, Kim TM, Lee JH
- KMID: 2543995
- Clin Mol Hepatol.
- 2023 Jul;29(3):794-809.
- doi: 10.3350/cmh.2023.0057
Background/Aims: Chronic hepatitis B (CHB) is a risk factor for non-Hodgkin lymphoma (NHL). Our recent study suggested that antiviral treatment may reduce the incidence of NHL in CHB patients. This... -
- CITED
-
- Close
- SHARE
-
- Close
- Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study
-
Lee CH, Choi GH, Choi HY, Han S, Jang ES, Chon YE, Chang Y, Kim KA, Kim DY, Yim HJ, Kim HL, Jeong SH, Kim IH
- KMID: 2543994
- Clin Mol Hepatol.
- 2023 Jul;29(3):779-793.
- doi: 10.3350/cmh.2023.0110
Background/Aims: To eliminate hepatitis B virus (HBV) and hepatitis C virus (HCV) according to the World Health Organization (WHO) criteria in 2021, this study investigated the national core indicators representing... -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients
-
Wu X, Xu X, Zhou J, Sun Y, Ding H, Xie W, Chen G, Ma A, Piao H, Wang B, Chen S, Meng T, Ou X, Yang HI, Jia J, Kong Y, You H
- KMID: 2543992
- Clin Mol Hepatol.
- 2023 Jul;29(3):747-762.
- doi: 10.3350/cmh.2023.0121
Background/Aims: Existing hepatocellular carcinoma (HCC) prediction models are derived mainly from pretreatment or early on-treatment parameters. We reassessed the dynamic changes in the performance of 17 HCC models in patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”
-
Emiroglu HH
- KMID: 2543997
- Clin Mol Hepatol.
- 2023 Jul;29(3):812-812.
- doi: 10.3350/cmh.2023.0132
-
- CITED
-
- Close
- SHARE
-
- Close
- Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”
-
Jeong S, Lim Y, Lee SK, Han HW
- KMID: 2543996
- Clin Mol Hepatol.
- 2023 Jul;29(3):810-811.
- doi: 10.3350/cmh.2023.0129
-
- CITED
-
- Close
- SHARE
-
- Close
- Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging
-
Hwang YJ, Bae JS, Lee Y, Hur BY, Lee DH, Kim H
- KMID: 2543991
- Clin Mol Hepatol.
- 2023 Jul;29(3):733-746.
- doi: 10.3350/cmh.2023.0034
Background/Aims: The microvascular invasion (MVI) of hepatocellular carcinoma (HCC) involves a wide histological spectrum, and it is unclear whether the degree of MVI correlates with patient prognosis or imaging findings.... -
- CITED
-
- Close
- SHARE
-
- Close
- Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis
-
Wong YJ, Nguyen VH, Yang HI, Li J, Le MH, Wu WJ, Han NX, Fong KY, Chen E, Wong C, Rui F, Xu X, Xue Q, Hu XY, Leow WQ, Goh GBB, Cheung R, Wong G, Wong VWS, Yu MW, Nguyen MH
- KMID: 2543989
- Clin Mol Hepatol.
- 2023 Jul;29(3):705-720.
- doi: 10.3350/cmh.2023.0004
Background/Aims: Chronic hepatitis B (CHB) and fatty liver (FL) often co-exist, but natural history data of this dual condition (CHB-FL) are sparse. Via a systematic review, conventional meta-analysis (MA) and... -
- CITED
-
- Close
- SHARE
-
- Close
- KASL clinical practice guidelines for management of autoimmune hepatitis 2022
-
The Korean Association for the Study of the Liver (KASL)
- KMID: 2543981
- Clin Mol Hepatol.
- 2023 Jul;29(3):542-592.
- doi: 10.3350/cmh.2023.0087
-
- CITED
-
- Close
- SHARE
-
- Close
- Erratum to ‘Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in directacting antiviral failure in South Korea’ [Clin Mol Hepatol 2023;29:496-509]
-
Kim KA, Lee S, Park HJ, Jang ES, Lee YJ, Cho SB, Kim YS, Kim IH, Lee BS, Chung WJ, Ahn SH, Kim S, Jeong SH
- KMID: 2544006
- Clin Mol Hepatol.
- 2023 Jul;29(3):830-830.
- doi: 10.3350/cmh.2022.0345e
-
- CITED
-
- Close
- SHARE
-
- Close
- Erratum to ‘Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?’ [Clin Mol Hepatol 2023;29:367-370]
-
Oh JH, Sinn DH
- KMID: 2544005
- Clin Mol Hepatol.
- 2023 Jul;29(3):828-829.
- doi: 10.3350/cmh.2023.0054e
-
- CITED
-
- Close
- SHARE
-
- Close
